

NHSBT Finance Report

August 2022

Contents	Page
Executive Summary	2
Financial Performance Headlines	3-4
NHSBT – Summary I&E Statement	5
Divisional I&E statements	6-9
Cash & Debtors	10
Contribution Statement	11

Executive Summary

NHSBT is reporting a surplus of £9.7m in the year to date August 2022, £6.5m higher than budget (a surplus of £3.2m). This mostly reflects lower expenditure on the change programme in Blood/Group and positive variances in DDTS budgets. This position will quickly reverse, however, due to the impact of the NHS pay award, the higher headcount/resourcing underway in Blood Supply and a catch up in group services spend during the rest of the year.

Given the uncertainty and highly volatile environment Blood Supply are currently facing, the forecast reported in this report has been updated to the latest view (month 5 forecast), which is now a deficit of £17.0m, £8.9m worse than budget (a deficit of £8.1m). This reflects the impact of the NHS pay award and national insurance levy combined with further deterioration of the Blood Supply position as a result of the additional resourcing that is being implemented in support of both blood collections and manufacturing. Although it would normally be expected that DHSC will fund the increased pay award, the forecast currently assumes that this will not be the case.

The higher deficit than planned (reported in the current forecast) arises from:

- Productivity savings in blood collection that will no longer be delivered (£2m)
- A further adverse cost variance of (£3.6m) in Blood Supply as a result of higher overtime, temporary labour and headcount in Blood Collection and higher temporary labour costs in Processing and Hospital Services.
- Additional marketing (£2m) in response to ongoing stock challenge
- The higher pay award (£3.5m)
- The costs of DCD Hearts in ODT that are being funded by cash reserves (£3.5m)

This is offset by:


- Surpluses in Clinical Services (£1.4m)
- Lower transformation costs (£3.6m), primarily due to capitalisation of Blood Technology Modernisation Costs and the re-profiling of Colindale works

As a result of the above, the cash surplus in Blood/Group of around £7m that was available in 2022/23 is likely to be utilised and will not be available as hoped to support pricing in 2023/24.

2022/23 NHSBT Financial Performance Headlines - August 2022


Year to date surplus of £9.7m for NHSBT overall, £6.5m ahead of plan

Blood and Group Net Income & Expenditure (excl. Change Programme and Plasma)




Blood and Group ahead of plan, driven by underspends in Group Services - detail on page 5 & 6.

Clinical Services Net Income & Expenditure (Business unit contribution)




£0.9m favourable variance – combination of higher activity and vacancies across Business Units – detail on page 7.

Organ Donation & Transplantation Net Funding & Expenditure




**ODT broadly in line with plan - detail on page 8
In addition, TES is £0.2m ahead of plan.**

Blood and Group Change Programme Full Year Outturn




**Full year forecast £13.4m, versus the £17m plan.
The difference is mostly due to re-categorisation of Blood Tech Modernisation expenditure to capital.**

NHSBT Cash Flow 2022/23



Forecast cash balance at the end of March 2023 is £36m

NHSBT I&E Full Year Outturn



Month 5 (interim) forecast now reporting a deficit of £17m.

2022/23 NHSBT Financial Performance Headlines – August 2022

Surpluses across all Divisions in the year to date.

Year to Date	£9.7m surplus vs £3.2m budget surplus	Blood/Group	+£5.5m	Lower transformation and group services spend, only partially offset by Blood Supply pressures.	
		Plasma	+£0.0m	In line with plan.	
		Clinical Services	+£0.9m	Increased activity across most business units, plus lower costs due to unfilled vacancies.	
		OTDT	+ £0.1m	ODT (-£0.2m) – transformation spend. TES (+£0.2m) – predominately driven by pay underspends.	

Full Year Forecast (Month 5)	£17.0m deficit forecast vs £8.1m deficit budget	Blood/Group	-£5.2m	Pressures in Blood Supply, partially offset by Change Programme underspends – detail on 5 & 6.	
		Plasma	-£0.7m	ABC allocation £0.8m lower than budget estimates (carry forward as cash to 2023/24).	
		Clinical Services	+£1.4m	Increased activity across most business units, plus lower costs due to unfilled vacancies.	
		OTDT	-£4.3m	ODT (-£3.4m) – Transformation & (now also) DCD Hearts funded from cash. TES (-£0.9m) – Cornea activity lower than plan.	

Cash and Debtors	Cash balance £85m	Debtor Days	17 days – ahead of target (22 days)	
		90+ day overdues	£0.5m (within £0.5m - £1.0m target range).	
		Cash	Cash balance at then end of August 2022 was £85m. £36m forecast at end March 2023.	


Arrow direction indicates the direction of performance vs previous month. Colour demonstrates performance against standards and expectations

NHSBT Summary I&E statement - August 2022

Aug			Blood and Group	WTE		Year to Date			Prev. Yr Actual	Budget	M05 Forecast	Variance
Budget	Actual	Variance		Budget	Actual	Budget	Actual	Variance				
1,036	1,036	0	Programme Funding - Corporate		5,178	5,178	0	11,461	12,428	11,200	(1,228)	
25,664	25,662	(2)	Blood & Components Income		127,767	127,867	100	292,274	306,827	307,027	200	
306	404	99	Blood Supply Other Income		1,437	1,688	251	3,864	3,512	4,087	575	
507	691	184	Group Services Income		2,561	2,989	428	5,272	6,091	6,124	33	
27,512	27,792	280	Blood and Group Income		136,944	137,721	778	312,872	328,857	328,438	(420)	
213	194	(19)	Blood Supply Cost of Sales	0	805	(617)	(1,422)	(2,305)	0	0	0	
(13,537)	(13,568)	(31)	Blood Supply Operations	2,462	(68,048)	(68,893)	(845)	(163,543)	(163,952)	(172,002)	(8,050)	
(14,885)	(15,235)	(350)	Group Services	1,220	(74,688)	(71,367)	3,321	(168,879)	(182,936)	(183,286)	(350)	
(1,248)	134	1,382	Change Programme	0	(5,263)	(1,550)	3,713	(12,213)	(16,999)	(13,377)	3,622	
(29,457)	(28,475)	982	Blood and Group Expenditure	3,683	(147,193)	(142,426)	4,767	(346,940)	(363,886)	(368,664)	(4,778)	
(1,945)	(682)	1,263	Blood and Group Total	3,683	(10,250)	(4,705)	5,545	(34,068)	(35,029)	(40,227)	(5,198)	
Plasma for Medicine												
1,176	1,215	40	Programme Funding - Plasma		5,878	6,764	887	29,483	14,107	10,457	(3,650)	
682	828	146	Plasma for Diagnostics Income		2,727	2,470	(257)	1	7,500	7,500	0	
1,857	2,043	186	Plasma Funding		8,605	9,234	629	29,484	21,607	17,957	(3,650)	
0	0	0	Plasma for Medicine Cost of Sales	0	0	0	0	1,076	0	0	0	
(879)	(1,064)	(186)	Plasma for Medicine	122	(4,343)	(4,973)	(629)	(29,484)	(16,493)	(9,113)	1,863	
(879)	(1,064)	(186)	Plasma Expenditure		(4,343)	(4,973)	(629)	(28,408)	(16,493)	(13,630)	2,863	
979	979	0	Plasma for Medicine Total	122	4,262	4,262	0	1,076	5,113	4,326	(787)	
Clinical Services												
374	373	(1)	Programme Funding - Clinical Services		1,870	1,866	(4)	4,162	4,489	4,489	(0)	
5,918	5,948	30	Clinical Services Income		29,032	29,501	469	69,057	72,420	73,239	819	
6,292	6,321	29	Clinical Services Income		30,902	31,367	465	73,219	76,909	77,728	819	
(5,395)	(5,440)	(45)	Clinical Services Operations	803	(26,838)	(25,834)	1,004	(59,448)	(65,839)	(65,685)	154	
0	(98)	(98)	Clinical Services Change Programme	0	0	(584)	(584)	(1,671)	(3,751)	(3,319)	432	
(5,395)	(5,538)	(143)	Clinical Services Expenditure		(26,838)	(26,418)	419	(61,119)	(69,590)	(69,004)	586	
897	784	(113)	Clinical Services Total	803	4,065	4,949	884	12,101	7,319	8,724	1,404	
Organ Donation & Transplantation												
6,665	6,699	33	Programme Funding (DHSC and Other UK Health Authorities)		33,326	33,369	43	81,504	79,983	81,316	1,334	
170	170	0	Programme Funding - Opt Out		851	851	0	0	2,041	2,041	0	
284	322	38	NHSE Funding		1,419	1,532	113	1,921	3,404	3,912	508	
7,119	7,191	72	ODT Income		35,595	35,751	156	83,425	85,428	87,270	1,842	
(5,693)	(5,777)	(84)	Organ Donation and Transplantation Operations	490	(30,303)	(29,691)	612	(63,376)	(71,926)	(72,080)	(154)	
(358)	(551)	(193)	Organ Donation and Transplantation Change Programme	30	(1,791)	(2,711)	(919)	(10,500)	(4,488)	(9,551)	(5,063)	
(6,052)	(6,328)	(277)	ODT Expenditure		(32,094)	(32,402)	(307)	(73,876)	(76,414)	(81,630)	(5,217)	
1,067	862	(205)	ODT Total	520	3,501	3,350	(151)	9,550	9,015	5,640	(3,375)	
Tissues and Eye Services												
1,550	1,309	(241)	Tissue & Eye Services Income		6,730	6,653	(76)	15,062	17,937	16,921	(1,016)	
46	46	0	Programme Funding - Tissue and Eye Services		231	231	0	0	554	554	0	
1,596	1,355	(241)	TES Income		6,961	6,884	(76)	15,062	18,491	17,475	(1,016)	
(1,080)	(1,022)	59	Tissue and Eye Services Operations	153	(5,346)	(5,028)	318	(12,468)	(13,043)	(12,942)	101	
(1,080)	(1,022)	59	TES Expenditure		(5,346)	(5,028)	318	(12,468)	(13,043)	(12,942)	101	
516	334	(182)	TES Total	153	1,615	1,856	242	2,595	5,449	4,534	(915)	
NHSBT Summary												
44,377	44,703	326	Income		219,007	220,959	1,952	514,063	531,293	528,868	(2,425)	
(42,862)	(42,426)	436	Expenditure	5,281	(215,815)	(211,247)	4,568	(522,810)	(539,426)	(545,871)	(6,445)	
1,515	2,277	762	NHSBT Surplus/(Deficit)	5,281	5,192	9,712	6,520	(8,747)	(8,133)	(17,004)	(8,871)	

Blood and Group - August 2022

Blood Supply (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Blood and Component Income			127.8	127.9	0.1	306.8	307.0	0.2
Other Blood Supply Income			1.4	1.7	0.3	3.5	4.1	0.6
Total Income			129.2	129.6	0.4	310.3	311.1	0.8
Cost of Sales - Blood Component Stock Movement			0.8	(0.6)	(1.4)	0.0	0.0	0.0
Blood Donation	1,420	1,455	(31.5)	(31.7)	(0.2)	(75.3)	(79.7)	(4.4)
Manufacturing, Testing & Issue	732	701	(27.4)	(27.6)	(0.2)	(66.4)	(68.8)	(2.4)
Logistics	310	309	(9.1)	(9.6)	(0.5)	(22.2)	(23.4)	(1.3)
Total Expenditure	2,462	2,466	(67.2)	(69.5)	(2.3)	(164.0)	(172.0)	(8.1)



Blood Supply Operating Surplus/(Deficit)	2,462	2,466	62.0	60.0	(1.9)	146.4	139.1	(7.3)
Group Services (incl. Change Programme)	1,220	1,138	(72.2)	(64.7)	7.5	(181.4)	(179.3)	2.1
Blood and Group Surplus/(Deficit)	3,683	3,603	(10.2)	(4.7)	5.5	(35.0)	(40.2)	(5.2)

Group Services detail on page 6

Year to date, Blood Supply are reporting £1.9m adverse cost variance against plan. This is largely driven by fixed cost movement in stock, as red cell stocks are significantly lower than the April opening position.

The forecast adverse cost variance of £7.3m for the full year assumes that planned productivity savings of £2.0m in the second half of the year will no longer be delivered, plus the impact of the increased pay award (£2.0m). Due to the ongoing recruitment and stock challenge, the latest recruitment and resourcing plans will result in higher headcount than plan in both blood collection and manufacturing, along with high levels of agency staff and overtime, bringing the forecast variance spend to c£8.1m adverse.

Group Services - August 2022

Group Services (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			5.2	5.2	0.0	12.4	11.2	(1.2)
Group Services Income			0.7	0.8	0.1	1.7	1.7	0.0
Medical			0.7	0.9	0.2	1.6	1.6	0.0
Research & Development			1.2	1.3	0.1	2.8	2.8	0.0
Total Income			7.7	8.2	0.4	18.5	17.3	(1.2)
Chief Executive and Board	4	3	(0.3)	(0.3)	0.0	(0.8)	(0.8)	(0.0)
Donor Experience	191	169	(9.8)	(9.9)	(0.1)	(23.9)	(26.0)	(2.1)
Quality	128	124	(3.5)	(3.2)	0.3	(8.6)	(8.4)	0.2
Estates & Facilities	80	77	(20.5)	(19.7)	0.8	(49.0)	(49.2)	(0.2)
Finance	111	96	(2.9)	(2.9)	0.0	(7.3)	(7.8)	(0.6)
Strategy and Transformation	14	10	(0.4)	(0.5)	(0.1)	(1.0)	(1.1)	(0.1)
People	153	153	(4.5)	(4.2)	0.3	(11.0)	(11.5)	(0.4)
Digital, Data and Technology Services	301	258	(17.8)	(15.8)	2.0	(44.3)	(41.8)	2.5
Research & Development	47	38	(2.7)	(2.6)	0.0	(6.3)	(6.3)	(0.0)
Medical	193	182	(7.1)	(7.1)	0.0	(18.0)	(17.8)	0.3
Miscellaneous and Capital Charges	0	0	(5.2)	(5.2)	0.0	(12.5)	(12.4)	0.1
Total Expenditure	1,220	1,111	(74.7)	(71.4)	3.3	(182.9)	(183.3)	(0.3)
Operating Surplus/(Deficit)	1,220	1,111	(66.9)	(63.2)	3.7	(164.4)	(166.0)	(1.5)
Change Programme	0	26	(5.3)	(1.5)	3.7	(17.0)	(13.4)	3.6
Group Services Surplus/(Deficit)	1,220	1,138	(72.2)	(64.7)	7.5	(181.4)	(179.3)	2.1

Year to date, Group Services (excluding the Change Programme) is reporting a £3.7m positive variance against plan. This is partially due to expenditure profiling in Estates (minor works and maintenance spend), combined with directorate wide vacancies and underspends in DDTS (re-categorisation of BTM expenditure to capital). The latest forecast expects this underspend to significantly reverse as pressures such as the agreed 2022/23 pay deal, additional cost of resourcing the Testing and Development Programme (reported in Finance and DDTS), and the unfunded National Insurance levy (£1.2m) result in an full year outturn adverse variance of £1.5m.

The Blood and Group change programme is, however, forecasting a large underspend, also due to the re-categorisation of Blood Technology Modernisation expenditure to capital and the re-profiling of Colindale Estates works into 2023/24.

Clinical Services - August 2022 (operating contributions - pre ABC analysis)

(£)m	WTE		Year to Date Actual			Full Year Forecast		
	Budget	Actual	Budget	Actual	Variance	Budget	M05 Forecast	Variance
Red Cell Immunohematology (inc Reagents and IBGRL)								
Income			9.3	9.3	0.0	22.6	22.5	(0.1)
Expenditure			(7.0)	(6.7)	0.4	(17.2)	(16.8)	0.4
RCI - direct contribution	250	228	2.3	2.6	0.4	5.3	5.7	0.4
Histocompatibility & Immunogenetics								
Income			6.5	6.7	0.2	16.0	16.2	0.2
Expenditure			(6.4)	(6.3)	0.1	(15.7)	(15.7)	(0.0)
H&I - direct contribution	177	169	0.1	0.4	0.3	0.3	0.5	0.2
Pathology Total - WTE / direct contribution								
	427	396	2.4	3.1	0.7	5.6	6.2	0.5
Therapeutic Apheresis Services								
Income			4.8	6.0	1.1	11.8	13.2	1.4
Expenditure			(3.8)	(4.2)	(0.4)	(9.4)	(9.9)	(0.5)
TAS - direct contribution	99	94	1.0	1.8	0.7	2.5	3.3	0.8
Cord Blood Bank and British Bone Marrow Registry								
Income - prices			3.1	3.0	(0.2)	7.6	7.5	(0.1)
Expenditure			(1.4)	(1.3)	0.1	(3.4)	(3.3)	0.1
SCGT - direct contribution	46	44	1.8	1.7	(0.1)	4.2	4.3	0.1
CBC								
Income			1.6	0.7	(0.9)	4.4	3.2	(1.2)
Expenditure			(1.5)	(1.8)	(0.3)	(3.6)	(3.6)	(0.0)
CBC - direct contribution	37	33	0.1	(1.1)	(1.3)	0.8	(0.4)	(1.2)
Cellular & Molecular Therapies (exc CBC)								
Income			5.5	5.7	0.2	14.4	14.7	0.3
Expenditure			(4.3)	(3.7)	0.5	(10.4)	(10.2)	0.3
CMT I&E	108	98	1.2	2.0	0.8	4.0	4.5	0.6
CAGT Total - WTE / direct contribution								
	290	269	4.1	4.3	0.2	11.4	11.7	0.3
Transfusion excl. R&D / Medical (within Group Services)								
	39	36	(0.5)	(0.3)	0.2	(1.2)	(1.4)	(0.2)
DTS Management								
	46	34	(1.9)	(1.5)	0.4	(4.8)	(4.5)	0.3
TOTAL - WTE / Operating Surplus/(Deficit)								
	803	736	4.1	5.5	1.5	11.1	12.0	1.0
Change Programme								
	0	2	0.0	(0.6)	(0.6)	(3.8)	(3.3)	0.4
TOTAL - WTE / Clinical Services Surplus/(Deficit)								
	803	738	4.1	4.9	0.9	7.3	8.7	1.4

At the end of August, Clinical Services (pre ABC analysis) is reporting £1.5m ahead of plan (excluding change programme). This is predominately driven by higher income across TAS and CMT combined with vacancies reported within the Division. The M05 forecast implies that this operating surplus will decrease with as the impact of the pay award and reduced activity (income) run rates.

Summary by Business Unit:

RCI; driven primarily by unfilled vacancies in the first half of they year. The underspend run rate is expected to reduce once the pay award arrears is paid from M06.


H&I; contribution above plan driven by strong service performance year to date, albeit this is expected to flatten through the remainder of the year as the pay-award is paid and activity levels reduce inline with plan.

TAS; year to date, procedures are 12% ahead of target, resulting in a positive position against plan. The forecast expects activity to continue to be ahead of plan, albeit, at a lower run rate.

CBC; adverse position against plan due to slippages in high value contracts and the up front purchase of stock

CMT; driven by favourable service income. The forecast implies that this will continue throughout the remainder of the year, although at a slower rate, as the post covid activity catch up reported in Q1 is expected to flatten

Income growth in Clinical Services



Note: Excludes Medical and R&D funding.

Organ Donation and Transplant – August 2022

ODT I&E	WTE		Year to Date Actual			Full Year Forecast		
(£)m	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			28.9	28.8	(0.1)	69.4	69.0	(0.4)
Other UK Health Authorities Funding			5.3	5.5	0.2	12.6	14.3	1.7
NHSE Funding			1.4	1.5	0.1	3.4	3.9	0.5
Total Funding			35.6	35.8	0.2	85.4	87.3	1.8
Operating Expenditure	490	470	(30.3)	(29.7)	0.6	(71.9)	(72.1)	(0.2)
Transformation	30	24	(1.8)	(2.7)	(0.9)	(4.5)	(9.6)	(5.1)
Total Expenditure	520	494	(32.1)	(32.4)	(0.3)	(76.4)	(81.6)	(5.2)
ODT Surplus/(Deficit)	520	494	3.5	3.3	(0.2)	9.0	5.6	(3.4)
Direct contribution to Group Services						(10.8)	(10.8)	0.0
ODT Deficit (funded by cash)						(1.8)	(5.2)	(3.4)

The ODT funding envelope for 2022/23 is based on flat funding from DHSC. The resulting deficit at operational level (£1.8m) will be met from cash reserves.

The latest forecasts, however, reflect increased funding from both Scotland and Wales, improving the operating deficit by c£1.1m. Discussions however, will take place towards the end of the year to confirm if surpluses (if any) are to be returned, or form part of ODTs carried forward cash reserve to support future years.

The adverse cost pressures reported against Transformation (including DCD Hearts) will be funded by cash reserves carried forward from 2021/22, as requested by DHSC.

Going into 2023/24 the underlying deficit is set to increase further, reflecting an incremental increase to activity (per the ODT strategy) and inflation pressures vs flat funding over the SR21 period. This funding gap will need to be addressed well in advance of 2023/24.

Tissue and Eye Services – August 2022

Year to date, TES are beginning to see an income shortfall against plan, primarily driven by lower Cornea activity reported in Q2. The forecast implies that this position will worsen significantly throughout the remainder of the year.

TES I&E	WTE		Year to Date Actual			Full Year Forecast			
(£)m	Bud.	Per Act.	Bud.	Act.	Var.	Budget	Fcst.	Variance	
Income				7.0	6.9	(0.1)	18.5	17.5	(1.0)
Cost of Sales				(0.2)	(0.1)	0.1	(0.5)	(0.5)	0.0
Expenditure	153	140	(5.1)	(4.9)	0.2	(12.5)	(12.4)	0.1	
Surplus/(Deficit)	153	140	1.6	1.9	0.2	5.4	4.5	(0.9)	

Plasma for Medicines - August 2022

Plasma for Medicine	WTE		Year to Date			Full Year Forecast		
(£)m	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			5.9	6.8	0.9	14.1	10.5	(3.7)
Plasma for Diagnostics Income			2.7	2.5	(0.3)	7.5	7.5	0.0
Expenditure	122	132	(4.3)	(5.0)	(0.6)	(16.5)	(13.6)	2.9
Programme Surplus/(Deficit)	122	132	4.3	4.3	(0.0)	5.1	4.3	(0.8)

For 2022/23, the Plasma plan is fully funded by a combination of cash reserves and Plasma for Diagnostics income.

The 2022/23 budget envelope estimated a group service contribution of £5.1m, however, ABC analysis/allocation has indicated in an overhead allocation of £4.3m. The balance (£0.8m) will be treated as re-profiled funding carried forward into 2023/24.

Cash Flow – as at August 2022

	Actual Apr-22 £k	Actual May-22 £k	Actual Jun-22 £k	Actual Jul-22 £k	Forecast Aug-22 £k	Forecast Sep-22 £k	Forecast Oct-22 £k	Forecast Nov-22 £k	Forecast Dec-22 £k	Forecast Jan-23 £k	Forecast Feb-23 £k	Forecast Mar-23 £k	Total £k
Opening bank balance	64,676	72,432	75,293	69,908	89,346	85,291	78,311	68,360	65,947	63,723	64,665	51,997	64,676
Receipts													
Debtors & Other Receipts	33,604	39,970	34,671	34,788	36,027	38,071	39,205	38,051	38,203	39,168	39,437	40,773	451,970
Revenue Cash Limit	0	0	0	23,833	5,038	6,751	6,108	6,108	6,108	6,108	6,108	6,109	72,272
Revenue Cash Limit - Pensions Uplift	0	0	0	3,680	1,840	0	933	933	933	933	933	1,015	11,200
Capital Cash Limit	0	0	0	3,000	0	0	4,000	0	4,000	0	3,000	3,000	17,000
Total Receipts	33,604	39,970	34,671	65,301	42,905	44,822	50,246	45,092	49,244	46,209	49,478	50,897	552,442
Payments													
Staff Expenses	6,743	21,016	21,338	21,413	20,986	30,000	26,999	24,452	23,567	23,838	23,665	31,713	275,730
Other Revenue Payments	18,359	15,949	18,378	24,022	25,932	20,802	21,561	22,054	26,401	19,929	26,045	27,693	267,126
Capital Charges Less DH Credit Due	0	0	0	0	0	0	10,437	0	0	0	10,437	0	20,874
Capital Payments	746	144	340	427	42	1,000	1,200	1,000	1,500	1,500	2,000	7,100	17,000
Total Payments	25,848	37,109	40,055	45,863	46,961	51,802	60,197	47,506	51,468	45,267	62,147	66,506	580,730
Closing bank balance	72,432	75,293	69,908	89,346	85,291	78,311	68,360	65,947	63,723	64,665	51,997	36,388	36,388

Debtor Days (Target is 22 days)	17	14	13	18	17
YTD BPPC By Value % (Target is 95%)	86.9%	95.5%	97.2%	96.9%	90.0%
YTD BPPC By Number % (Target is 95%)	92.8%	93.3%	93.5%	94.0%	93.3%

Overdue Debtors NBS/ODT £000's	1-30 Days overdue £000's	31-60 Days overdue £000's	61-90 Days overdue £000's	>90 Days overdue £000's	Total Overdue £000's
Total Overdue Debtors	4,968	2,101	739	536	8,343

Top 5 > 90 days Overdue Debtors £000's	Jul-22		Aug-22	
	>90 Days overdue £000's	Total Overdue £000's	>90 Days overdue £000's	Total Overdue £000's
KINGSTON HOSPITAL NHS FOUNDATION TRUST	83	296		
GATESHEAD HEALTH NHS FOUNDATION TRUST	63	284		
HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST	79	177	79	251
HCA INTERNATIONAL LTD	79	96		
IMPERIAL COLLEGE HEALTHCARE NHS TRUST	47	86	53	789
ISLE OF WIGHT NHS TRUST			48	201
GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST			34	76
UNIVERSITY HOSPITALS BRISTOL AND WESTON NHS FOUNDATION TRUST			31	153
LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST				
ROYAL BERKSHIRE NHS FOUNDATION TRUST				
Total 5 Overdue Debtors	352	938	246	1,471
Other Debtors	328	9,247	290	6,873
Total Overdue Debtors	680	10,185	536	8,343

Notional Split	£m
Blood	11.7
Clinical Services	7.0
ODT	5.3
Plasma	12.4
NHSBT Total	36.4

>90 DAYS OVERDUE	Profile by Month													
	Actual Apr-22 £000s	Actual May-22 £000s	Actual Jun-22 £000s	Actual Jul-22 £000s	Actual Aug-22 £000s	Actual Sep-22 £000s	Actual Oct-22 £000s	Actual Nov-22 £000s	Actual Dec-22 £000s	Actual Jan-23 £000s	Actual Feb-23 £000s	Actual Mar-23 £000s		
Target Range Between £0.5m and £1.0m														
Ledger Balance at month end	330	413	686	680	536									

Contribution Statement– as at August 2022

Post allocation of costs via the ABC model

Year to date Actual £m	Blood & Components inc. R&D	Plasma	Pathology		CAGT				TES	ODT	NHSBT
			RCI	H&I	CMT	CBC	SCDT	TAS			
Income/Funding											
Prices	129.6	0.0	8.8	5.9	5.5	0.0	1.9	5.7	6.6	0.0	164.0
Central Funding from DHAs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	5.3
Grant in Aid (DHSC Funding)	3.7	6.9	0.2	0.8	0.1	0.0	1.1	0.1	0.4	29.5	42.8
Other	3.2	2.3	0.4	0.2	0.2	0.7	0.0	0.2	0.0	1.7	8.8
Total Income/Funding	136.5	9.2	9.4	6.8	5.8	0.7	3.0	6.0	7.0	36.4	221.0
Expenditure											
Variable Costs	(15.4)	(0.4)	(0.8)	(1.4)	(0.8)	(0.6)	(0.3)	(1.7)	(1.1)	(2.6)	(25.3)
Variable Contribution	121.1	8.7	8.6	5.4	5.0	0.1	2.7	4.3	5.9	33.9	195.7
Direct Costs	(53.7)	(4.5)	(5.3)	(3.2)	(2.9)	(1.2)	(1.6)	(2.4)	(4.1)	(29.4)	(108.3)
Direct Contribution	67.5	4.2	3.3	2.2	2.1	(1.1)	1.1	1.9	1.8	4.4	87.5
Direct Support Costs	(44.6)	(1.1)	(2.2)	(0.6)	(1.9)	(0.4)	(0.9)	(0.6)	(1.2)	(4.2)	(57.6)
Total Allocated Costs	(113.6)	(6.0)	(8.4)	(5.3)	(5.6)	(2.2)	(2.9)	(4.7)	(6.5)	(36.2)	(191.2)
Total Unallocated Costs	(9.7)	(0.5)	(0.7)	(0.5)	(0.5)	(0.2)	(0.2)	(0.4)	(0.5)	(3.2)	(16.5)
Operating Net Surplus / (Deficit)	13.1	2.6	0.4	1.1	(0.2)	(1.6)	(0.1)	0.9	0.0	(3.0)	13.3
Transformation	(1.4)	-	(0.2)	(0.1)	(0.1)	(0.0)	(0.1)	(0.1)	-	(1.6)	(3.6)
Net Surplus / (Deficit) Inc Transformation	11.8	2.6	0.2	1.0	(0.3)	(1.7)	(0.2)	0.8	0.0	(4.6)	9.7
Budget	7.4	2.7	(0.2)	0.7	(1.4)	(0.5)	(0.1)	0.3	(0.6)	(5.1)	3.2
Variance	4.4	0.0	0.4	0.3	1.0	(1.2)	(0.1)	0.6	0.6	0.5	6.5
RAG	G	G	G	G	G	R	A	G	G	G	G

Blood at "Green" but results from the favourable group services and change programme position
 CBC – reporting red driven by slippages in high value contracts.
 Stem Cell and Donation – amber as CBB issues are behind plan.